How to Value a Podiatry Practice in 2026

Podiatry is one of the most misunderstood specialties in healthcare M&A. Sellers often anchor to a multiple they heard from a general dental broker, and buyers walk in assuming it trades like primary care. Neither is right. A podiatry practice with a strong surgical program and a diabetic foot care contract with a local wound care center is a fundamentally different asset than a mall-based routine nail care practice — and the multiples reflect that.

I've watched podiatry groups sell anywhere from 2.5x SDE for a thin owner-dependent solo practice to 6x+ SDE for a surgical-heavy group with ambulatory surgery center (ASC) ownership. Let me walk you through what actually drives these numbers.

The Podiatry Valuation Range

Most podiatry practices trade between 3.0x and 6.0x SDE, with the vast majority clustering around 3.5-4.5x. The outliers on both ends are instructive:

• 2.5-3.0x SDE: Solo practitioner, mostly routine care (nail debridement, callus care), no surgical volume, heavy Medicare concentration, no associate.
• 3.5-4.5x SDE: Typical well-run solo or two-doctor group with a balanced mix of routine care, biomechanics, and office-based procedures.
• 5.0-6.0x SDE: Multi-provider group with surgical volume at a hospital or ASC, diabetic foot care contracts, and a real orthotics lab.
• 6.0x+ SDE / EBITDA deals: Practices acquired by PE-backed platforms like US Foot & Ankle Specialists or Upperline Health, typically with $1M+ EBITDA.

Revenue multiples are less useful in podiatry because the payer mix and procedure mix vary so wildly. A $1.2M practice can have SDE anywhere from $180K to $550K depending on how the owner structured compensation, surgical collections, and DME (durable medical equipment) revenue. Always work off normalized SDE.

Why Surgical Capability Changes Everything

The single biggest valuation swing in podiatry comes from whether the selling DPM has hospital privileges and a meaningful surgical case volume. A podiatrist doing 8-12 bunionectomies, hammertoe corrections, and Achilles repairs per month at a local ASC is generating $25K-$60K per case in collections. That's the difference between a $1M revenue practice and a $1.8M revenue practice from the same chair time.

Buyers pay up for surgical volume because:

• ASC ownership interest — if the seller owns equity in a surgery center, that K-1 distribution income often adds $75K-$200K of recurring cash flow that gets valued separately at 4-6x.
• Higher per-patient revenue — a surgical visit plus global period is worth 10-20x a routine nail trim from a collections standpoint.
• Referral moats — surgical practices build relationships with endocrinologists, vascular surgeons, and orthopedic groups that a nail-care practice simply doesn't have.

The catch: surgical volume often doesn't transfer. If the selling DPM built their book over 25 years of hospital call and medical staff relationships, a young buyer may not inherit privileges easily, and referral sources follow relationships. Smart buyers discount surgical revenue 20-35% unless the seller commits to a 2-3 year transition.

Diabetic Foot Care: The Hidden Value Driver

Diabetic foot care is the most underappreciated asset in podiatry valuation. A practice with 600-900 active diabetic patients seen on a recurring 9-week cycle has something close to a subscription revenue model — and buyers recognize that.

The math is compelling. A Medicare diabetic foot exam plus nail debridement (CPT 11721, G0127) reimburses $55-$85 per visit. At 700 patients cycling every 9 weeks, that's roughly 4,050 visits per year, or $250K-$340K of almost entirely recurring revenue. Layer on therapeutic shoes under the Medicare Therapeutic Shoe Bill ($180-$450 per patient per year, A5500 codes) and you have another $90K-$200K of annual revenue tied to the same diabetic panel.

Buyers value this revenue stream at a premium because:

• It's recurring and predictable — diabetics don't stop needing foot care.
• It's Medicare, so there's no payer concentration risk from a commercial contract loss.
• It drives downstream surgical referrals when ulcers or Charcot foot develop.
• It's the primary wedge that wound care center contracts get written against.

If you have formal contracts with a hospital wound care center, a dialysis clinic, or a skilled nursing facility chain, document them. These contracts are worth 15-30% of the annual revenue they generate when a buyer underwrites the deal.

Orthotic Revenue: Margin, Not Just Revenue

Custom orthotics are where podiatry practices print money — and where sellers most often fail to tell the story correctly. A pair of custom functional orthotics costs the practice $85-$140 from a lab like KLM, Richie, or Paris Orthotics, and sells cash-pay for $400-$650. That's a 70-80% gross margin product in a healthcare business that otherwise grinds on 55% clinical overhead.

Practices dispensing 15-25 pairs per month at $500 average are adding $90K-$150K of high-margin revenue on top of their professional fees. A practice with its own in-house orthotics lab (direct milling, scanner, own technician) captures even more margin and gets credit for the equipment as a hard asset. Buyers love this because it's the rare segment of podiatry revenue that isn't captive to a CMS fee schedule.

When preparing for sale, break out orthotic and DME revenue as a separate line item on your P&L. Buyers will apply the overall SDE multiple to it, but if you can show it as a recurring, high-margin cash business, you can sometimes negotiate a separate higher multiple on that segment.

The PE Roll-Up Reality

Podiatry is actively being rolled up. Upperline Health (backed by NEA and Silversmith Capital), US Foot & Ankle Specialists, Foot & Ankle Specialists of the Mid-Atlantic, and regional platforms are buying aggressively. Their pricing framework looks more like dental DSO math than traditional medical practice math.

For a practice with $750K+ EBITDA, expect platform pricing of 6-9x EBITDA with 15-25% rolled as equity in the platform. Add-on pricing for smaller ($250K-$500K EBITDA) practices runs 4.5-6x EBITDA, almost always with a 3-year employment agreement and a non-compete covering a 10-15 mile radius.

The platforms underwrite to three things: surgical volume at an ASC they can eventually own or partner with, diabetic panel size, and the ability to install a second or third provider without losing the existing patient base. If your practice checks those three boxes, you're in the conversation. If not, you're selling to another DPM and the math is capped at 4-5x SDE.

What Kills Podiatry Practice Value

Medicare concentration above 75%. Routine foot care audits and LCD (local coverage determination) changes are a constant risk. A practice that's 90% Medicare routine care is essentially betting the business on CMS policy. Buyers discount heavily.

The owner does all the surgery. If 100% of the practice's surgical volume belongs to the selling DPM, a buyer is realistically looking at a 40-60% revenue cliff in year one. That gets priced in brutally.

Old equipment. A practice still using film X-ray, no digital charting, and a 2005 treatment chair is signaling $60K-$120K of deferred capex. Buyers deduct it dollar-for-dollar from their offer.

No associate, no mid-level. Solo practices with no NP, PA, or associate DPM cap out around 3.5x SDE because the owner-dependency risk is uncapped. Adding even a part-time associate for 18 months before sale can move your multiple by 0.5-1.0x.

How to Maximize Your Exit

If you're 2-3 years from selling, the moves that matter most are:

Build your diabetic panel deliberately. Partner with local endocrinologists and primary care groups. A practice that can show 800+ active diabetic patients has a completely different valuation conversation than one with 300.

Bring in an associate or a foot-and-ankle surgeon. Even two days a week of additional provider coverage proves the practice isn't you, and it increases SDE by expanding capacity without increasing your hours.

Document your orthotics business. Track pairs dispensed, average selling price, and lab cost. A clean orthotics P&L is often worth 0.2-0.5x on your overall multiple.

Secure your lease and your hospital privileges for the buyer. A 7-10 year lease and a clear path to credentialing continuity removes two of the biggest friction points in a podiatry deal. And get your pre-sale preparation done 18 months ahead — surprises during due diligence kill podiatry deals more often than price disagreements do.

The Bottom Line

Podiatry valuation is a story about mix — payer mix, procedure mix, and provider mix. A practice that tells a clean story about surgical volume, diabetic panel depth, and orthotic margin will trade at the top of the range. One that hands a buyer a single-column P&L and says "it's a foot practice, figure it out" will trade at the bottom. The difference between those two outcomes, on a $1.5M practice, is often $600K-$900K of sale price.